BRPI0606501A2 - derivados de ácido 3-fenilpropiÈnico, composto, composição farmacêutica que o contém, utilização do composto e método de tratamento e/ou profilaxia de enfermidades e condições mediadas por gama receptor ativado por proliferador de peroxissome (ppary) - Google Patents
derivados de ácido 3-fenilpropiÈnico, composto, composição farmacêutica que o contém, utilização do composto e método de tratamento e/ou profilaxia de enfermidades e condições mediadas por gama receptor ativado por proliferador de peroxissome (ppary)Info
- Publication number
- BRPI0606501A2 BRPI0606501A2 BRPI0606501-5A BRPI0606501A BRPI0606501A2 BR PI0606501 A2 BRPI0606501 A2 BR PI0606501A2 BR PI0606501 A BRPI0606501 A BR PI0606501A BR PI0606501 A2 BRPI0606501 A2 BR PI0606501A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- gamma
- alkyl
- prophylaxis
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DERIVADOS DE áCIDO 3-FENILPROPIÈNICO, COMPOSTO, COMPOSIçãO FARMACêUTICA QUE O CONTéM, UTILIZAçãO DO COMPOSTO E MéTODO DE TRATAMENTO E/OU PROFILAA DE ENFERMIDADES E COMPOSIçõES MEDIADAS POR FAMA RECEPTOR ATIVADO POR PROLIFERADOR DE PEROXISSOME (PPAR<sym>). A invenção refere-se a novos compostos, os quais são derivados de ácido 3-fenliproplónico de acordo da fórmula I em que W representa o grupo COOH ou seus bioésteres, ou o group -COO-C~ 1~-C~ 4~-alquila; Y representa NH, N-C~ 1~-C~ 10~-alquila, O, ou S; Z representa NH, N-C~ 1~-C~ 10~-alquila, N-arila, N-heteroarila, S, ou O; X representa O, S, NH, N-C~ 1~-C~ 10~-alquila, N-arila, NSO~ 2~-C~ 1~-C~ 10~-alquila, N-SO~ 2~-arila, ou N-SO~ 2~-heteroarila; R~ 1~ a R~ 6~ cada um independentemente representa um átomo de hidrogênio ou umsubstituinte definido na descrição; A é tal como definido na descrição; n representa um inteiro de 0 a 4, inclusive; e seus sais farmaceuticamente aceitáveis. Os compostos são os ligantes do receptor PPAR-gama e são de utilidade como medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL372332A PL372332A1 (pl) | 2005-01-19 | 2005-01-19 | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| PCT/EP2006/050234 WO2006077206A1 (en) | 2005-01-19 | 2006-01-17 | New 3-phenylpropionic acid derivatives and their use as ppar- gamma rezeptor liganden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606501A2 true BRPI0606501A2 (pt) | 2009-06-30 |
Family
ID=36046977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606501-5A BRPI0606501A2 (pt) | 2005-01-19 | 2006-01-17 | derivados de ácido 3-fenilpropiÈnico, composto, composição farmacêutica que o contém, utilização do composto e método de tratamento e/ou profilaxia de enfermidades e condições mediadas por gama receptor ativado por proliferador de peroxissome (ppary) |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7309791B2 (pt) |
| EP (1) | EP1874745B1 (pt) |
| JP (1) | JP2008527021A (pt) |
| KR (1) | KR100889447B1 (pt) |
| CN (1) | CN101098862A (pt) |
| AT (1) | ATE448214T1 (pt) |
| AU (1) | AU2006207492B8 (pt) |
| BR (1) | BRPI0606501A2 (pt) |
| CA (1) | CA2590575C (pt) |
| CY (1) | CY1109678T1 (pt) |
| DE (1) | DE602006010353D1 (pt) |
| DK (1) | DK1874745T3 (pt) |
| ES (1) | ES2336358T3 (pt) |
| HR (1) | HRP20090647T1 (pt) |
| IL (1) | IL183564A0 (pt) |
| MX (1) | MX2007008114A (pt) |
| NO (1) | NO20074173L (pt) |
| PL (2) | PL372332A1 (pt) |
| PT (1) | PT1874745E (pt) |
| RS (1) | RS51215B (pt) |
| RU (1) | RU2369602C2 (pt) |
| SI (1) | SI1874745T1 (pt) |
| UA (1) | UA89940C2 (pt) |
| WO (1) | WO2006077206A1 (pt) |
| ZA (1) | ZA200705889B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371841A1 (pl) * | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| AU2006311523A1 (en) * | 2005-11-07 | 2007-05-18 | Irm Llc | Oxazole and thiazole PPAR modulator |
| WO2009132310A1 (en) * | 2008-04-25 | 2009-10-29 | Wisconsin Alumni Research Foundation | Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth |
| JP5357894B2 (ja) * | 2008-12-01 | 2013-12-04 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
| WO2016003917A1 (en) * | 2014-07-03 | 2016-01-07 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| US10080757B2 (en) | 2016-03-11 | 2018-09-25 | Wisconsin Alumni Research Foundation | Inhibitors of UDP-galactopyranose mutase |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1552125A (en) | 1975-06-07 | 1979-09-05 | Lilly Industries Ltd | 2-acylamino oxazoles |
| JPS58125039A (ja) | 1982-01-21 | 1983-07-25 | Konishiroku Photo Ind Co Ltd | 写真用２当量イエロ−カプラ− |
| US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| AU3959193A (en) | 1992-04-10 | 1993-11-18 | Smithkline Beecham Plc | Heterocyclic compounds and their use in the treatment of type II-diabetes |
| WO1995025107A1 (en) | 1994-03-12 | 1995-09-21 | Yuhan Corporation | Triazole compounds and processes for the preparation thereof |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| PL339660A1 (en) * | 1997-10-02 | 2001-01-02 | Sankyo Co | Derivatives of amidocarboxylic acids |
| JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| EP1210345B1 (en) | 1999-09-08 | 2004-03-03 | Glaxo Group Limited | Oxazole ppar antagonists |
| FR2808798A1 (fr) | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| EP1414806A1 (en) | 2001-07-30 | 2004-05-06 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| WO2003011814A1 (en) | 2001-07-30 | 2003-02-13 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| PL371841A1 (pl) * | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| PL372356A1 (pl) * | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
-
2005
- 2005-01-19 PL PL372332A patent/PL372332A1/pl unknown
-
2006
- 2006-01-12 US US11/332,709 patent/US7309791B2/en not_active Expired - Fee Related
- 2006-01-17 UA UAA200709387A patent/UA89940C2/ru unknown
- 2006-01-17 JP JP2007551662A patent/JP2008527021A/ja active Pending
- 2006-01-17 SI SI200630532T patent/SI1874745T1/sl unknown
- 2006-01-17 CA CA2590575A patent/CA2590575C/en not_active Expired - Fee Related
- 2006-01-17 PL PL06703590T patent/PL1874745T3/pl unknown
- 2006-01-17 DK DK06703590T patent/DK1874745T3/da active
- 2006-01-17 ES ES06703590T patent/ES2336358T3/es not_active Expired - Lifetime
- 2006-01-17 CN CNA2006800017398A patent/CN101098862A/zh active Pending
- 2006-01-17 EP EP06703590A patent/EP1874745B1/en not_active Expired - Lifetime
- 2006-01-17 PT PT06703590T patent/PT1874745E/pt unknown
- 2006-01-17 KR KR1020077018743A patent/KR100889447B1/ko not_active Expired - Fee Related
- 2006-01-17 AT AT06703590T patent/ATE448214T1/de active
- 2006-01-17 AU AU2006207492A patent/AU2006207492B8/en not_active Ceased
- 2006-01-17 WO PCT/EP2006/050234 patent/WO2006077206A1/en not_active Ceased
- 2006-01-17 RS RSP-2010/0003A patent/RS51215B/sr unknown
- 2006-01-17 BR BRPI0606501-5A patent/BRPI0606501A2/pt not_active IP Right Cessation
- 2006-01-17 HR HR20090647T patent/HRP20090647T1/hr unknown
- 2006-01-17 DE DE602006010353T patent/DE602006010353D1/de not_active Expired - Lifetime
- 2006-01-17 RU RU2007131423/04A patent/RU2369602C2/ru not_active IP Right Cessation
- 2006-01-17 MX MX2007008114A patent/MX2007008114A/es active IP Right Grant
-
2007
- 2007-03-06 US US11/714,984 patent/US7629370B2/en not_active Expired - Fee Related
- 2007-05-30 IL IL183564A patent/IL183564A0/en unknown
- 2007-07-18 ZA ZA200705889A patent/ZA200705889B/xx unknown
- 2007-08-14 NO NO20074173A patent/NO20074173L/no not_active Application Discontinuation
-
2009
- 2009-12-30 CY CY20091101346T patent/CY1109678T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| NO20066041L (no) | Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer | |
| ATE275559T1 (de) | Aromatische amin-derivate verwendbar als pharmazeutische mittel | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
| NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| CY1109678T1 (el) | Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα | |
| NO20055421L (no) | Kinolinderivater som fosfodiestrase-inhibitorer | |
| NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
| SI1716152T1 (sl) | Kondenzirane heterociklične spojine in njihova uporaba kot antagonisti metabotropnega receptorja za zdravljenje gastrointestinalnih motenj | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| NO20062983L (no) | Sulfonamid-derivater for behandling av sykdommer | |
| MA33166B1 (fr) | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose | |
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
| SE0303480D0 (sv) | Benzofuranes | |
| WO2004066952A3 (en) | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | |
| CY1110622T1 (el) | Νεα παραγωγα 3-φαινυλοπροπιονικου οξεος για την αντιμετωπιση του διαβητη | |
| EA200970496A1 (ru) | Соединения 2-алкилиндазола для лечения некоторых расстройств цнс | |
| TW200635911A (en) | Sulfanyl substituted phenyl methanones | |
| DE60143671D1 (de) | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor-antagonists | |
| DE60321700D1 (de) | Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUI DADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2208 DE 30/04/2013. |